The FDA inspected the company’s medical device operations from Sept. 16 to 20 and then again Nov. 14 and 15. During the investigation, the FDA found manufacturing methods were “not in conformity with the current good manufacturing practice requirements of the Quality System regulations” of the agency.
Conformis responded to the initial inspection’s concerns on Oct. 8, outlining long-term corrective action for issues raised, and took further action. But the FDA’s Dec. 10 letter stated that the responses did not address its immediate concerns about product sterility. The FDA asked that Conformis provide “objective evidence” that its sterilizers could pass validation for routine operating conditions.
More articles on orthopedic devices:
4 pillars of Stryker’s growth strategy from CEO Kevin Lobo
Zimmer Biomet in 2019: 6 things to know
14 spine devices receive FDA 510(k) clearance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.